Stress & Premenstrual Symptoms Study

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

April 1, 2016

Primary Completion Date

December 1, 2021

Study Completion Date

December 1, 2021

Conditions
PMDDStressMood
Interventions
DRUG

Sertraline

Sertraline will be provided at a dose of 50 mg daily for up to 3 weeks, depending on the length of a woman's luteal phase. Medication will be taken only during the luteal phase. Women will initiate sertraline treatment upon determining that they have ovulated (using a urine luteinizing hormone (LH) Kit) and remain on sertraline until onset of their next menstrual period at which time they will stop taking the medication.

Trial Locations (1)

21205

Center for Women's Reproductive Mental Health, Johns Hopkins University School of Medicine, Baltimore

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Johns Hopkins University

OTHER

NCT02777372 - Stress & Premenstrual Symptoms Study | Biotech Hunter | Biotech Hunter